Alnylam Halts Legal Battle Over Pfizer-BioNTech’s COVID-19 Vaccine Patent Claims

Alnylam Pharmaceuticals has announced the cessation of a district court patent dispute concerning the COVID-19 vaccine developed by Pfizer and BioNTech. The company has approached a Delaware federal judge with a request to declare that the Pfizer-BioNTech vaccine does not infringe upon its mRNA-related patents. This development may serve as a precursor to an appeal. For more details on this matter, visit the original report by Law360.